In spite of that big broken water main, the FDA managed to make a bit of news before everything shuts down for the holiday. Three key items:
1. The agency isn’t ready to approve AstraZeneca’s drug Seroquel XR for major depressive disorder, the company said. The drug — an extended release version of the company’s blockbuster [...]

Popularity: 8% [?]

A gradual loss of blood flow to the brain over years or decades could be a major trigger for Alzheimer’s disease, according to a new study.
Up to now, what provokes the debilitating disease has remained a mystery, even if the mechanism causing the damage is well understood.
The new research suggests that an insufficient supply of [...]

Popularity: 9% [?]

Two proteins which work together in the brain’s blood vessels present a double whammy in Alzheimer’s disease.
Not only do they lessen blood flow in the brain, they also reduce the rate at which the brain is able to remove amyloid beta, the protein that builds up in toxic quantits in the brains of patients with [...]

Popularity: 13% [?]

Drugs used to treat Alzheimer’s patients’ cognitive symptoms are also a safe and effective therapy for behavioral and psychological symptoms such as aggression, wandering and paranoia, according to U.S. researchers.

They reviewed nine studies that examined the effectiveness of three popular cholinesterase inhibitors in managing Alzheimer’s patients’ behavioral and psychological symptoms, and found the drugs were [...]

Popularity: 13% [?]

Anavex Life Sciences Corp. (”ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition of Neuropsychopharmacology. Currently in the late pre-clinical [...]

Popularity: 17% [?]

Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer’s disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears in the December 2008 edition of Clinical Interventions in Aging.
Investigators from the Indiana University School of Medicine, the Regenstrief Institute and Wishard Health [...]

Popularity: 13% [?]

Is widespread screening of the elderly for Alzheimer’s disease and other problems of memory a good idea?
Some experts don’t think so. But an analysis of published research and survey data by the Alzheimer’s Foundation of America suggests that the critics have it wrong. The body of evidence, the group says, “shatters unsubstantiated criticism” about the [...]

Popularity: 12% [?]

Anavex Life Sciences Corp. (”ANAVEX”) (OTCBB), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience, which took place November 15-19, 2008 [...]

Popularity: 21% [?]

A study published in the November issue of the Journal of Alzheimer’s Disease (Volume 15:3) suggests the reliability of the Alzheimer’s Disease Assessment Scale - Cognitive (ADAS-Cog) may vary and possess the ability to affect clinical trial outcomes.

Moreover, this study further suggests that ADAS-Cog rater training and experience are factors that contribute to variances seen [...]

Popularity: 14% [?]

The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it provided a grant of $185,000 to Varinel, Inc., an emerging pharmaceutical company dedicated to developing drugs that can prevent neuronal degeneration and improve brain function. The grant will assist Varinel in advancing the preclinical development of its multifunctional lead compounds, VAR10300 (also known as M30).

VAR10300 [...]

Popularity: 19% [?]